Edition:
United States

Rigel Pharmaceuticals Inc (RIGL.OQ)

RIGL.OQ on NASDAQ Stock Exchange Global Select Market

2.39USD
26 May 2017
Change (% chg)

$-0.03 (-1.24%)
Prev Close
$2.42
Open
$2.42
Day's High
$2.45
Day's Low
$2.39
Volume
102,813
Avg. Vol
310,236
52-wk High
$4.37
52-wk Low
$1.94

RIGL.OQ

Chart for RIGL.OQ

About

Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted drugs in the therapeutic areas of immunology, oncology and immuno-oncology. The Company's clinical programs include clinical studies of fostamatinib, an oral spleen tyrosine kinase (SYK)... (more)

Overall

Beta: 1.42
Market Cap(Mil.): $292.62
Shares Outstanding(Mil.): 122.43
Dividend: --
Yield (%): --

Financials

  RIGL.OQ Industry Sector
P/E (TTM): -- 137.90 17.41
EPS (TTM): -0.68 -- --
ROI: -81.46 -8.48 -5.42
ROE: -84.08 -11.31 -4.68

BRIEF-Rigel announces Q1 loss per share $0.13

* Rigel announces first quarter 2017 financial results and provides company update

May 02 2017

BRIEF-Rigel announces Tavaliss as proprietary name for Fostamatinib in the U.S.

* Rigel announces Tavalisse™ as proprietary name for Fostamatinib in the united states

Apr 27 2017

BRIEF-Rigel submits NDA to FDA for fostamatinib in chronic itp

* Rigel submits new drug application to fda for fostamatinib in chronic itp

Apr 17 2017

BRIEF-Rigel Q4 loss per share $0.16

* Rigel announces fourth quarter 2016 and year end 2016 financial results and provides company update

Mar 07 2017

BRIEF-Stephen Sherwin to from Rigel Pharmaceuticals board

* Rigel Pharmaceuticals - on feb 22, stephen sherwin notified co of his decision to resign as a member of board effective as of may 11, 2017

Feb 24 2017

BRIEF-Great Point Partners LLC reports 7.47 pct passive stake in Rigel Pharmaceuticals Inc

* Great Point Partners LLC reports 7.47 passive stake in Rigel Pharmaceuticals Inc as on January 31, 2017 - SEC filing Source text (http://bit.ly/2kAJjwK) Further company coverage:

Feb 10 2017

BRIEF-Rigel reports closing of public offering of common stock

* Rigel announces closing of public offering of common stock and full exercise of option to purchase additional shares Source text for Eikon: Further company coverage:

Feb 03 2017

BRIEF-Rigel says public offering of 20 mln shares priced at $2 per share

* Says public offering of 20.0 million common shares priced at $2.00per share

Jan 31 2017

BRIEF-Rigel announces proposed public offering of common stock

* Rigel Pharmaceuticals Inc- Proceeds to be used to fund research and development activities, commercial preparation and for general corporate purposes Source text for Eikon: Further company coverage:

Jan 30 2017

BRIEF-Rigel Pharmaceuticals announces updates from clinical program of Fostamatinib in patients with chronic immune thrombocytopenic purpura

* Rigel Pharmaceuticals announces updates from clinical program of Fostamatinib in patients with chronic immune thrombocytopenic purpura

Jan 30 2017

More From Around the Web

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF78.60 -0.50
Roche Holding Ltd. (ROG.S) CHF266.60 -0.60
Roche Holding Ltd. (RO.S) CHF267.75 +0.25
Merck & Co., Inc. (MRK.N) $64.92 -0.12
Sanofi SA (SASY.PA) €87.74 +0.43
AstraZeneca plc (AZN.L) 5,227.00 +18.00
Abbott Laboratories (ABT.N) $44.71 +0.76

Earnings vs. Estimates